Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions
Drugmakers are increasingly relying on artificial intelligence to accelerate clinical trials and regulatory filings, slashing weeks off processes that often slow down development, according to executives and analysts. While AI hasn’t yet cracked the code for discovering groundbreaking new drugs, it’s already making a dent in the “messy middle” of drug development. This matters since the timeline remains brutal. Companies report that developing a drug can take around a decade and cost close to $2 billion. Even when results seem promising, the slow grind of trial setup and paperwork can drag timelines out much longer.